• Discover Astex
    • Our Mission & Values
    • Our Leadership Team
    • Research Fellows
    • Our History
    • Corporate Social Responsibility
    • Environmental Sustainability
  • R&D
    • Clinical Pipeline
    • Pyramid™ Discovery Platform
    • Oncology and CNS Discovery
    • Sustaining Innovation Postdocs
  • Partnering
  • Our People & Culture
    • Career Opportunities
  • Media
    • Press Releases
    • Conferences & Meetings
    • Presentations & Publications
    • Interactive Scientific Resources
      • Interactive Software
    • Astex in the News
  • Contact
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu
You are here: Home1 / 20082 / SuperGen’s PIM Kinase Inhibitor, SGI-1776, Causes Tumor Regression...

SuperGen’s PIM Kinase Inhibitor, SGI-1776, Causes Tumor Regression in AML Xenograft Models

13 June 2008/in 2008, News

SuperGen’s PIM Kinase Inhibitor, SGI-1776, Causes Tumor Regression in AML Xenograft Models

https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg 0 0 webadmin https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg webadmin2008-06-13 12:58:582016-11-28 12:59:20SuperGen’s PIM Kinase Inhibitor, SGI-1776, Causes Tumor Regression in AML Xenograft Models

© Astex Pharmaceuticals
All rights reserved

astex

Useful links

  • Home
  • Sitemap
  • Privacy Policy
  • Terms of Use
  • Legal
  • LinkedIn

Member of the Otsuka Group

A selection of photos on this website
is courtesy of Valerio Berdini

Link to: Astex Announces New Drug Discovery Alliance with Janssen Pharmaceutica N.V. Link to: Astex Announces New Drug Discovery Alliance with Janssen Pharmaceutica N.V. Astex Announces New Drug Discovery Alliance with Janssen Pharmaceutica N.V. Link to: SuperGen’s JAK2 Inhibitor, SGI-1252, Inhibits in Vivo Tumor Cell Proliferation Link to: SuperGen’s JAK2 Inhibitor, SGI-1252, Inhibits in Vivo Tumor Cell Proliferation SuperGen’s JAK2 Inhibitor, SGI-1252, Inhibits in Vivo Tumor Cell Prol...
Scroll to top Scroll to top Scroll to top